Check Before You Invest : Oxygenta Pharmaceutical Ltd

Snapshot

Q.1 Which industry/sub-sector does Oxygenta Pharmaceutical Ltd belong to?

Oxygenta Pharmaceutical Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Oxygenta Pharmaceutical Ltd a good quality company?

Oxygenta Pharmaceutical Ltd is a weak quality company, based on a inconsistent 10-year financial track record.

Q.3 Is Oxygenta Pharmaceutical Ltd undervalued or overvalued?

Oxygenta Pharmaceutical Ltd appears Undervalued, as its key valuation ratios are below with their past averages.

Q.4 Is Oxygenta Pharmaceutical Ltd a good buy now?

Oxygenta Pharmaceutical Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Oxygenta Pharmaceutical Ltd?

Oxygenta Pharmaceutical Ltd revenue growth is 175.7% for FY-2025, which is above its 5-year CAGR of 51.44%, indicating faster growth.

Q.2 Return on Asset of Oxygenta Pharmaceutical Ltd?

Oxygenta Pharmaceutical Ltd Return on Asset is -15.24%, which is below its 5-year historical median of -6.4%, indicating deteriorated asset utilization efficiency.

Q.3 Cash conversion cycle of Oxygenta Pharmaceutical Ltd?

Oxygenta Pharmaceutical Ltd Cash conversion cycle is -2 days, below its 5-year historical median of -0 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.

Q.4 Gross Profit margin of Oxygenta Pharmaceutical Ltd?

Oxygenta Pharmaceutical Ltd Gross profit margin which is the profit after deduction of direct costs, is -9.6% for FY-2025, which is in line with its 5-year median of -9.6%, indicating stable margins.

Q.5 Operating Profit Margin of Oxygenta Pharmaceutical Ltd?

Oxygenta Pharmaceutical Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -8.77% for FY-2025, which is in line with its 5-year median of -8.77% indicating stable margins.

Q.6 Net Profit Margin of Oxygenta Pharmaceutical Ltd?

Oxygenta Pharmaceutical Ltd Net Profit Margin is -8.86% for FY-2025, is in line with with its 5-year median of -8.78%, indicating stable margins.

	Current Level	5-year Historic Median
Gross Profit Margin	-9.6	-9.6
Operating Profit Margin	-8.77	-8.77
Net Profit Margin	-8.86	-8.78

Q.7 Debt to Equity ratio of Oxygenta Pharmaceutical Ltd?

Oxygenta Pharmaceutical Ltd Debt-to-Equity ratio is -2.49, which is lower with the industry average of 0.27, indicating lower debt levels in the industry.

Q.8 Debt to cash flow from operations of Oxygenta Pharmaceutical Ltd?

Oxygenta Pharmaceutical Ltd Debt to cash flow from operations is 23.91, which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Oxygenta Pharmaceutical Ltd?

Promoters hold 56.54% of the Oxygenta Pharmaceutical Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Oxygenta Pharmaceutical Ltd vs industry peers?

Oxygenta Pharmaceutical Ltd revenue CAGR is 51.44%, compared to the industry median CAGR of 8.30%, indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth	175.7	8.3
Gross Profit Growth	0	14.7
Operating Profit Growth	0	11.4
Net Profit Growth	0	NAN

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover	1.72	0.81
ROE	-	9.49
ROCE	-	11.91
Cash Conversion Cycle (days)	-1.81	85

Valuation & price assessment

Q.1 Stock return of Oxygenta Pharmaceutical Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 17.3% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price CAGR	17.3%	49.4%	22.2%	-37.5%

Q.3 Valuation ratios of Oxygenta Pharmaceutical Ltd vs historical?

The current P/E is lower that its historical median.

Q.4 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	-	12.97	31.09
Price to Book	-4.91	-4.79	2.85
Price to Sales	1.78	2.33	2.79
EV to EBITDA	-16.03	-17.68	15.87

Check more companies

6. Wockhardt

7. Pfizer

8. Piramal Pharma

9. Acutaas Chemicals

10. Astrazeneca Pharma I

Check trending companies

1. Tata Elxsi Ltd.

2. Shree Cement Ltd.

3. Amara Raja Energy & Mobility Ltd.

4. Vishal Mega Mart Ltd.

5. Acme Solar Holdings Ltd.